Drugs & Therapy Perspectives

, Volume 2, Issue 12, pp 11–14 | Cite as

Choosing β-Blockers for Formulary Inclusion

Drug Economics and Quality of Life
  • 4 Downloads

Keywords

Factor Viii Felodipine Essential Tremor Labetalol Sotalol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yedinak KC. PharmacoEconomics 4: 104–121, 1993PubMedCrossRefGoogle Scholar
  2. 2.
    Frishman WH. Am Heart J 113: 1190–1198, 1987PubMedCrossRefGoogle Scholar
  3. 3.
    β-Blocker Heart Attack Trial Research Group. JAMA 247: 1707–1714, 1982CrossRefGoogle Scholar
  4. 4.
    Boissel JP, et al. Am J Cardiol 66: 251–260, 1990PubMedCrossRefGoogle Scholar
  5. 5.
    Norwegian Multicentre Study Group. N Engl J Med 304: 801–807, 1981CrossRefGoogle Scholar
  6. 6.
    Roberts R, et al. Circulation 83: 422–437, 1991PubMedCrossRefGoogle Scholar
  7. 7.
    Yusuf S, et al. Lancet 2: 273–276, 1980PubMedCrossRefGoogle Scholar
  8. 8.
    Viscoli CM, et al. Ann Intern Med 118: 99–105, 1993PubMedGoogle Scholar
  9. 9.
    Paolisso G, et al. Am Heart J 123: 103–110, 1992PubMedCrossRefGoogle Scholar
  10. 10.
    Swedberg K. Am J Cardiol 71: 30c–38c, 1993PubMedCrossRefGoogle Scholar
  11. 11.
    British National Formulary 25: 75–81, 1993Google Scholar
  12. 12.
    Tattersfield AE, Harrison RN. Drugs 25 (Suppl. 2): 227–231, 1983CrossRefGoogle Scholar
  13. 13.
    Waal-Manning HJ, Simpson FO. NZ Med J 103: 222, 1990Google Scholar
  14. 14.
    Gundlach CA, et al. Hosp Formul 25: 61–66, 1990Google Scholar
  15. 15.
    Pharand C, Chow MSS. Hosp Formul 27: 1094–1105, 1992Google Scholar

Copyright information

© Adis International Ltd 1993

Personalised recommendations